Gabriel Nogueira

• End-to-end ownership of the injectable portfolio performance in the private hospital channel, leading sell-in analysis, demand forecasting, stock coverage, and performance reporting. • Key contributor to the definition of the institutional pipeline and go-to-market strategy, with a strong focus on specialty medicines, including oncology (solid tumors and hematology) and biologics. • Led cross-functional supply alignment between commercial and operations to ensure sales planning accuracy, stock availability, and product continuity. • Managed and developed a team of marketing coordinators and analysts within the Institutional and Product management Marketing structure. • Actively involved in portfolio planning and new product launches, particularly in biologics and oncology therapies.

• Responsible for the strategy and management of Dramin B6 DL in the non-retail channel, the largest brand in the Business Unit and one of the company’s power brands, with strong governance and demand growth initiatives. • Led the strategy and execution of the launch of Hyblut, Hypera Pharma’s first biologic product, with a molecule representing over R$ 500 million annually in market value. • Conducted market assessment, financial feasibility, and go-to-market planning for new products, including the oncology portfolio (solid tumors and hematology). • Oversaw pricing and commercial monitoring of products across distributors and performed market analysis using IQVIA audits, such as NRC, Hospital Mapping, MDTR, MAP, NDDD). • Built and maintained strong relationships with internal stakeholders (cross-functional teams) and external ones such as distributors, medical and pharmaceutical societies, and high-potential healthcare institutions. Performance highlight: Dramin B6 DL revenue (MAT 03/2025): R$ 112M | Growth: +33.6%

• Responsible for the strategy and positioning of RX and OTC brands, developing marketing initiatives targeting physicians (prescription) and end-consumers. • Conducted promotional campaigns and training sessions with commercial teams. • Engaged with internal stakeholders (Regulatory Affairs, Medical, R&D, Market Intelligence, Logistics, and Sales) and external ones (KOLs and medical societies such as FBG, SOBED, SBMDN, SBP). • Developed and executed marketing plans, including market analysis and competitive differentiation (audits: PMB, NDDD, INTE, Audit Pharma, Close-up Market). • Monitored market trends and competitors’ activities (domestic and international). • Managed P&L, sales performance (sell-in, sell-out), and developed new products go-to-market strategies (line extensions and new brands). • Managed and developed a team of 3 analysts. Performance highlight: Gastro franchise revenue growth (MAT 01/2024): +45.1% vs. market +10.3% Recognition: Finalist – Lupa de Ouro 2024 with PEG-Lax

Completed a job rotation in 14 different areas, both technical and strategic, for an in-depth and comprehensive view of the pharmaceutical industry, including Controllership, Business Development, Sales, R&D, Production, Marketing, and Demand Force, gaining an understanding of the sector's processes and value chain.

Internship at a medical laboratory in a major hospital complex of metropolitan area of São Paulo. Receiving samples from over dozens of health centers. Obtaining experience in Immunology, Hematology, Biochemistry and Molecular Biology. Testing and analyzing of human blood, urine, spinal fluid or tissue. Receiving and releasing of tests results. Operation of laboratory equipment such as microscopes, cell counters and centrifuges.

Scientific research in Immunology at Paulista School of Medicine/UNIFESP. Evaluating the effects of the biological adjuvant Propionibacterium acnes over the antitumor response to melanoma in mice immunized with hybrid dendritic cells vaccine. Applying laboratory techniques, such as cell culture, enzymatic immuno linked assays and flow cytometry. Preparation of scientific reports, presentation of results and scientific articles.